Cargando…
Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race
BACKGROUND: This study investigates the association of clinical and demographic predictors with abdominal fat gain, measured using waist circumference (WC) and self-reported abdominal size. METHODS: We analyzed data from ACTG A5257, a clinical trial that randomized treatment-naïve HIV-infected parti...
Autores principales: | Bhagwat, Priya, Ofotokun, Ighovwerha, McComsey, Grace A, Brown, Todd T, Moser, Carlee, Sugar, Catherine A, Currier, Judith S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239079/ https://www.ncbi.nlm.nih.gov/pubmed/30465010 http://dx.doi.org/10.1093/ofid/ofy201 |
Ejemplares similares
-
Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s
por: Dirajlal-Fargo, Sahera, et al.
Publicado: (2016) -
Changes in the Fungal Marker β-D-Glucan After Antiretroviral Therapy and Association With Adiposity
por: Dirajlal-Fargo, Sahera, et al.
Publicado: (2019) -
Advanced Glycation End Products Associated With Cardiometabolic Biomarkers in Treated Human Immunodeficiency Virus Infection
por: El Kamari, Vanessa, et al.
Publicado: (2021) -
Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity
por: Lake, Jordan E., et al.
Publicado: (2015) -
Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia
por: Vardhanabhuti, Saran, et al.
Publicado: (2015)